Free Read Vesicular Stomatitis VirusBased Vaccines Protect Nonhuman Primates against Bundibugyo ebolavirus Ebook, PDF Epub
Vesicular Stomatitis VirusBased Vaccines Protect Nonhuman Primates against Bundibugyo ebolavirus
Description Vesicular Stomatitis VirusBased Vaccines Protect Nonhuman Primates against Bundibugyo ebolavirus.
Detail Book
- Vesicular Stomatitis VirusBased Vaccines Protect Nonhuman Primates against Bundibugyo ebolavirus PDF
- Vesicular Stomatitis VirusBased Vaccines Protect Nonhuman Primates against Bundibugyo ebolavirus EPub
- Vesicular Stomatitis VirusBased Vaccines Protect Nonhuman Primates against Bundibugyo ebolavirus Doc
- Vesicular Stomatitis VirusBased Vaccines Protect Nonhuman Primates against Bundibugyo ebolavirus iBooks
- Vesicular Stomatitis VirusBased Vaccines Protect Nonhuman Primates against Bundibugyo ebolavirus rtf
- Vesicular Stomatitis VirusBased Vaccines Protect Nonhuman Primates against Bundibugyo ebolavirus Mobipocket
- Vesicular Stomatitis VirusBased Vaccines Protect Nonhuman Primates against Bundibugyo ebolavirus Kindle
Book Vesicular Stomatitis VirusBased Vaccines Protect Nonhuman Primates against Bundibugyo ebolavirus PDF ePub
Vesicular Stomatitis Virus-Based Vaccines Protect Nonhuman ~ Vesicular Stomatitis Virus-Based Vaccines Protect Nonhuman Primates against Bundibugyo ebolavirus Chad E. Mire , 1, 2 Joan B. Geisbert , 1, 2 Andrea Marzi , 3 Krystle N. Agans , 1, 2 Heinz Feldmann , 3 and Thomas W. Geisbert 1, 2, *
Vesicular Stomatitis Virus-Based Vaccines Protect Nonhuman ~ Vesicular Stomatitis Virus-Based Vaccines Protect Nonhuman Primates against Bundibugyo ebolavirus Article (PDF Available) in PLoS Neglected Tropical Diseases 7(12):e2600 · December 2013 with 75 Reads
Vesicular Stomatitis Virus-Based Vaccines Protect Nonhuman ~ Geisbert TW, Daddario-Dicaprio KM, Geisbert JB, Reed DS, Feldmann F, et al. (2008) Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses. Vaccine 26: 6894–6900. doi: 10.1016/j.vaccine.2008.09.082 . View Article PubMed/NCBI
Vesicular stomatitis virus-based vaccines protect nonhuman ~ Among the most promising vaccines is a system based on recombinant vesicular stomatitis virus (VSV) which not only can protect nonhuman primates against EBOV and MARV when used as a single injection preventive vaccine but astonishingly showed 50–100% efficacy when employed as a postexposure treatment , , .
Vesicular stomatitis virus-based vaccines protect nonhuman ~ Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses Article in Vaccine 26(52):6894-900 · November 2008 with 86 Reads
Vesicular stomatitis virus-based vaccines protect nonhuman ~ Considerable progress has been made over the last decade in developing candidate preventive vaccines that can protect nonhuman primates against Ebola and Marburg viruses. A vaccine based on recombinant vesicular stomatitis virus (VSV) seems to be particularly robust as it can also confer protection when administered as a postexposure treatment.
Vesicular Stomatitis Virus–Based Vaccines against Lassa ~ vesicular stomatitis virus (VSV)–based vaccines on protective efficacy afforded by each vaccine in nonhuman primates. Vaccination with a VSV-based Lassa virus vaccine encoding
(PDF) Recombinant Vesicular Stomatitis Virus Vaccine ~ Immune protection of nonhuman primates against Ebola virus with single low- . Assessment of a vesicular stomatitis virus-based vaccine by use of the mouse . against Zaire ebolavirus that .
Vesicular Stomatitis Virus–Based Vaccines against Lassa ~ We demonstrated that previous vaccination with a vesicular stomatitis virus (VSV)–based Lassa virus vaccine does not alter protective efficacy of subsequent vaccination with a VSV-based Ebola virus vaccine. These findings demonstrate the utility of VSV-based vaccines against divergent viral pathogens, even when preexisting immunity to the vaccine vector is present.
(PDF) Ebola viral disease: A review literature ~ The newly discovered Bundibugyo ebolavirus . et al. Vesicular stomatitis virus-based vaccines . protect nonhuman primates against aerosol challenge with Ebola and .
Vesicular Stomatitis Virus-Based Ebola Vaccines With ~ Single immunization with a monovalent vesicular stomatitis virus-based vaccine protects nonhuman primates against heterologous challenge with Bundibugyo ebolavirus. Falzarano D, Feldmann F, Grolla A, Leung A, Ebihara H, Strong JE, Marzi A, Takada A, Jones S, Gren J, Geisbert J, Jones SM, Geisbert TW, Feldmann H. Falzarano D, et al. J Infect Dis .
Vesicular Stomatitis Virus-Based Vaccines Provide Cross ~ viruses Article Vesicular Stomatitis Virus-Based Vaccines Provide Cross-Protection against Andes and Sin Nombre Viruses Bryce M Warner 1,2,y, Derek R Stein 1,*,y, Rohit K Jangra 3, Megan M Slough 3, Patrycja Sroga 2, Angela Sloan 1, Kathy L Frost 2, Stephanie Booth 2, Kartik Chandran 3 and David Safronetz 1,2 1 Zoonotic Diseases and Special Pathogens, National Microbiology Laboratory,
Durability of a Vesicular Stomatitis Virus-Based Marburg ~ The filoviruses, Marburg virus (MARV) and Ebola virus, causes severe hemorrhagic fever with high mortality in humans and nonhuman primates. A promising filovirus vaccine under development is based on a recombinant vesicular stomatitis virus (rVSV) that expresses individual filovirus glycoproteins (GPs) in place of the VSV glycoprotein (G).
Vesicular Stomatitis Virus-Based Ebola Vaccines With ~ For Ebola virus (EBOV), 4 different species are known: Zaire, Sudan, Côte d’Ivoire, and Reston ebolavirus. The newly discovered Bundibugyo ebolavirus has been proposed as a 5th species.
Recombinant Vesicular Stomatitis Virus Vaccine Vectors ~ Recombinant Vesicular Stomatitis Virus Vaccine Vectors Expressing Filovirus Glycoproteins Lack Neurovirulence in Nonhuman Primates The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Mire, Chad E., Andrew D. Miller, Angela Carville, Susan V.
A Recombinant Vesicular Stomatitis Virus Ebola Vaccine / NEJM ~ Geisbert TW, Daddario-Dicaprio KM, Lewis MG, et al. Vesicular stomatitis virus-based Ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLoS Pathog 2008 ;4: e1000225 .
A Vesicular Stomatitis Virus-Based Hepatitis B Virus ~ Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses. Vaccine 26 : 6894-6900. [ PMC free article ] [ PubMed ]
Recombinant Vesicular Stomatitis Virus Vector Mediates ~ Recombinant vesicular stomatitis virus (VSV) vectors expressing homologous filoviral glycoproteins can completely protect rhesus monkeys against Marburg virus when administered after exposure and can partially protect macaques after challenge with Zaire ebolavirus.Here, we administered a VSV vector expressing the Sudan ebolavirus (SEBOV) glycoprotein to four rhesus macaques shortly after .
A vesicular stomatitis virus-based mucosal vaccine ~ A vesicular stomatitis virus-based mucosal vaccine promotes dendritic cell maturation and elicits preferable immune response against coxsackievirus B3 induced viral myocarditis . Download : Download full . F. Feldmann, A. Grolla, et al.Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola .
rVSV-ZEBOV vaccine - Wikipedia ~ Recombinant vesicular stomatitis virus–Zaire Ebola virus (rVSV-ZEBOV), also known as Ebola Zaire vaccine live and sold under the brand name Ervebo, is a vaccine for adults that prevents Ebola caused by the Zaire ebolavirus. When used in ring vaccination, rVSV-EBOV has shown a high level of protection. Around half the people given the vaccine have mild to moderate adverse effects that include .
Use of Single-Injection Recombinant Vesicular Stomatitis ~ Nipah virus (NiV) is a zoonotic pathogen that causes high case-fatality rates (CFRs) in humans. Two NiV strains have caused outbreaks: the Malaysia strain (NiVM), discovered in 1998–1999 in Malaysia and Singapore (≈40% CFR); and the Bangladesh strain (NiVB), discovered in Bangladesh and India in 2001 (≈80% CFR). Recently, NiVB in African green monkeys resulted in a more severe and lethal .
Recombinant Vesicular Stomatitis Virus Vaccine Vectors ~ Abstract. The filoviruses, Marburg virus and Ebola virus, cause severe hemorrhagic fever with high mortality in humans and nonhuman primates. Among the most promising filovirus vaccines under development is a system based on recombinant vesicular stomatitis virus (rVSV) that expresses an individual filovirus glycoprotein (GP) in place of the VSV glycoprotein (G).
Immunization with vesicular stomatitis virus vaccine ~ Silaghi, D. Kobasa, G. Kobinger, et al.Potent vesicular stomatitis virus-based avian influenza vaccines provide long-term sterilizing immunity against heterologous challenge J Virol, 84 (2010), pp. 4611-4618
Table - Vesicular Stomatitis Virus–Based Vaccines against ~ We demonstrated that previous vaccination with a vesicular stomatitis virus (VSV)–based Lassa virus vaccine does not alter protective efficacy of subsequent vaccination with a VSV-based Ebola virus vaccine. These findings demonstrate the utility of VSV-based vaccines against divergent viral pathogens, even when preexisting immunity to the vaccine vector is present.
Assessment of a Vesicular Stomatitis Virus-Based Vaccine ~ Protective efficacy of 1-dose vs. 2-dose immunization regimens. Mice were immunized intraperitoneally with either 2 doses (solid line with triangles) of 2×10 4 pfu of VSVΔG/ZEBOVGP (recombinant vesicular stomatitis virus in which the native glycoprotein [GP] gene has been deleted and functionally replaced with the Zaire ebolavirus Mayinga [ZEBOV-May] GP gene) given 28 days apart or a single .